Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Angiotensin-converting-enzyme inhibitors provide renal protection in patients with mild-to-moderate renal insufficiency (serum creatinine level, 3.0 mg per deciliter or less). We assessed the efficacy and safety of benazepril in patients without diabetes who had advanced renal insufficiency. METHODS: We enrolled 422 patients in a randomized, double-blind study. After an eight-week run-in period, 104 patients with serum creatinine levels of 1.5 to 3.0 mg per deciliter (group 1) received 20 mg of benazepril per day, whereas 224 patients with serum creatinine levels of 3.1 to 5.0 mg per deciliter (group 2) were randomly assigned to receive 20 mg of benazepril per day (112 patients) or placebo (112 patients) and then followed for a mean of 3.4 years. All patients received conventional antihypertensive therapy. The primary outcome was the composite of a doubling of the serum creatinine level, end-stage renal disease, or death. Secondary end points included changes in the level of proteinuria and the rate of progression of renal disease. RESULTS: Of 102 patients in group 1, 22 (22 percent) reached the primary end point, as compared with 44 of 108 patients given benazepril in group 2 (41 percent) and 65 of 107 patients given placebo in group 2 (60 percent). As compared with placebo, benazepril was associated with a 43 percent reduction in the risk of the primary end point in group 2 (P=0.005). This benefit did not appear to be attributable to blood-pressure control. Benazepril therapy was associated with a 52 percent reduction in the level of proteinuria and a reduction of 23 percent in the rate of decline in renal function. The overall incidence of major adverse events in the benazepril and placebo subgroups of group 2 was similar. CONCLUSIONS: Benazepril conferred substantial renal benefits in patients without diabetes who had advanced renal insufficiency. (ClinicalTrials.gov number, NCT00270426.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our trial confirms that the kidneyprotective effects of SGLT2 inhibitors extend to the broader population of persons with chronic kidney disease without type 2 diabetes, for whom ACE inhibitors are the only pharmacologic treatments that have been shown to prevent kidney failure.3,4”
From Dapagliflozin in Patients with Chronic Kidney Disease (2020) · cites this paper as [4]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
(2000) · Journal of the American Society of Nephrology · Cited by 1,718
Peterson, J. C., Adler, S., Burkart, J. M., Greene, T., Hebert, L. A., Hunsicker, L. G., King, A. J., Klahr, S., Massry, S. G., Seifter, J. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-10-199511150-00003 · Cited by 1,342
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823
Coresh, J., Astor, B. C., McQuillan, G., Kusek, J., Greene, T., Van Lente, F., & Levey, A. S. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32765 · Cited by 717
A SIMPLE METHOD OF ESTIMATING PROGRESSION OF CHRONIC RENAL FAILURE
Mitch, W. E., Walser, M., Buffington, G. A., & Lemann, J. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91974-7 · Cited by 459
Ruggenenti, P., Nefrologia”(GISEN), O. B. O. T. “. I. D. S. E. I., Perna, A., Mosconi, L., Pisoni, R., & Remuzzi, G. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00874.x · Cited by 434
Research works printed but not linked: 4
- 2001, Chin J Nephrol, 17, 77
- Hou FF, 2005, Zhonghua Yi Xue Za Zhi, 85, 458
- Zhang GH, 2005, Zhonghua Nei Ke Za Zhi, 44, 592
- Levey AS, 2000, J Am Soc Nephrol, 11, 155A
Cited by
Items 301–400 of 702
Dual RAS Therapy Not on Target, but Fully Alive
Heerspink, H. J. L., & de Zeeuw, D. (2010) · Nephron Clinical Practice · doi:10.1159/000315882 · Cited by 18
Arai, K., Morikawa, Y., Ubukata, N., & Sugimoto, K. (2020) · Hypertension Research · doi:10.1038/s41440-020-0495-0 · Cited by 19
Serrya, M. S., El‐Sheakh, A. R., & Makled, M. N. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119154 · Cited by 20
Ruiz‐Hurtado, G., & Ruilope, L. M. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvu023 · Cited by 19
Progression of Chronic Kidney Disease: Mechanisms and Interventions in Retardation
Balasubramanian, S. (2013) · Apollo Medicine · doi:10.1016/j.apme.2013.01.009 · Cited by 25
Influence of renin–angiotensin system on serum parathyroid hormone levels in uremic patients
Koiwa, F., Komukai, D., Hirose, M., Yoshimura, A., Ando, R., Sakaguchi, T., Komatsu, Y., Shinoda, T., Inaguma, D., Joki, N., et al. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-011-0534-x · Cited by 17
“We demonstrated significant decreases in iPTH levels with RASI administration, which has been an established renoprotective therapy for 10 years, with their beneficial antiproteinuric effects that delay progression of renal dysfunction [13, 14].”
BackgroundAdamczak, M., Kurnatowska, I., Naumnik, B., Stompór, T. P., Tylicki, L., & Krajewska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312941 · Cited by 21
Park, C. H., Kim, H. W., Park, J. T., Chang, T. I., Yoo, T., Lee, J., Sung, S. A., Jung, J. Y., Hyun, Y. Y., Oh, K., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.20824 · Cited by 17
Mantzourani, E., Λαιμού, Δ., Matsoukas, M., & Tselios, T. V. (2008) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/187152308786847799 · Cited by 17
“ACE inhibitors [89-96] were the first class of RAS blockers developed to reach the market, introduced in the early 1990’s.”
BackgroundSullivan, M. K., Carrero, J. J., Jani, B., Anderson, C., McConnachie, A., Hanlon, P., Nitsch, D., McAllister, D., Mair, F. S., Mark, P. B., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02628-2 · Cited by 18
Stopping Renin-Angiotensin System Inhibitors in Chronic Kidney Disease: Predictors of Response
Gonçalves, A., Khwaja, A., Ahmed, A. K., Kossi, M. E., & Nahas, M. E. (2011) · Nephron Clinical Practice · doi:10.1159/000330289 · Cited by 16
Thilly, N., Boini, S., Kessler, M., Briançon, S., & Frimat, L. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn566 · Cited by 16
Treatment of Abnormalities of Potassium Homeostasis in CKD
Palmer, B. F., & Clegg, D. J. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.06.001 · Cited by 19
Taylor, K., McLellan, J., Verbakel, J. Y. J., Aronson, J. K., Lasserson, D. S., Pidduck, N., Roberts, N. W., Fleming, S., O’Callaghan, C. A., Bankhead, C. R., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030596 · Cited by 18
Medicaid Expansion and Incidence of Kidney Failure among Nonelderly Adults
Thorsness, R., Swaminathan, S., Lee, Y., Sommers, B. D., Mehrotra, R., Nguyen, K. H., Kim, D., Rivera‐Hernandez, M., & Trivedi, A. N. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020101511 · Cited by 18
Lee, S., Kim, Y., Kim, W., Park, J., Shin, D., Hur, S., Kim, C.-J., Cho, M., Chae, S.-C., Jeong, M. H., et al. (2008) · Circulation Journal · doi:10.1253/circj.cj-08-0088 · Cited by 16
Heerspink, H. J. L. (2011) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2011.04.001 · Cited by 17
Tekale, S. S., Jaiwal, B. V., & Padul, M. V. (2016) · Food Chemistry · doi:10.1016/j.foodchem.2016.05.128 · Cited by 16
Starting Renal Replacement Therapy: Is It About Time?
Ku, E., McCulloch, C. E., & Johansen, K. L. (2019) · American Journal of Nephrology · doi:10.1159/000501510 · Cited by 16
Li, S., Chen, Y.-T., Yang, W.-C., Tarng, D., Lin, C., Yang, C., & Liu, W. (2012) · BMC Nephrology · doi:10.1186/1471-2369-13-89 · Cited by 16
“Inhibition of the RAAS by angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) prevents the progression of CKD in both diabetic and non-DM patients [6-12].”
BackgroundFeng, Z., Wu, L., Zhou, C., & Wang, C. (2024) · Organic Letters · doi:10.1021/acs.orglett.4c03303 · Cited by 15
Ichikawa, D., Kamijo‐Ikemori, A., Sugaya, T., Shibagaki, Y., Yasuda, T., Katayama, K., Hoshino, S., Igarashi-Migitaka, J., Hirata, K., & Kimura, K. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00460.2013 · Cited by 15
Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
Elliott, W. J. (2007) · Yearbook of Cardiology · doi:10.1016/s0145-4145(08)70049-2 · Cited by 15
Hyperkalemia in the Hypertensive Patient
Lakkis, J. I., & Weir, M. R. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0954-2 · Cited by 16
Schou, M., Torp-Pedersen, C. T., Gustafsson, F., Abdulla, J., & Køber, L. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.04.006 · Cited by 15
“[29] also showed that an angiotensin converting enzyme inhibitor slowed the decline in eGFR in patients with chronic kidney disease without diabetes.”
BackgroundACE up the sleeve – are vascular patients medically optimized
Coveney, A., O'Brien, G. C., & Fulton, G. J. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s15484 · Cited by 16
“An RCCT of benazepril use in nondiabetic patients with advanced renal insufficiency found that the treatment group had a 43% reduction in the risk of doubling of serum creatinine, end stage renal disease, or death.(26) ACE inhibition also reduced the rate of decline in renal function by 23%.”
Garrick, R. (2008) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)79136-3 · Cited by 15
Adaptation to Nephron Loss and Mechanisms of Progression in Chronic Kidney Disease
Taal, M. W., & Brenner, B. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10051-x · Cited by 17
Xiao, Q., Guan, Y., Li, C., Liu, L., Zhao, D., & Wang, H. (2018) · Renal Failure · doi:10.1080/0886022x.2018.1496934 · Cited by 19
“We found that Lotensin indeed reduced UPE and improved renal function in this stage as evidenced in this manuscript.”
BackgroundMethodInfluentialManagement of hypertension in chronic kidney disease
Zamboli, P., Nicola, L. D., Minutolo, R., Bertino, V., Catapano, F., & Conte, G. (2006) · Current Hypertension Reports · doi:10.1007/s11906-006-0029-4 · Cited by 16
“Conversely, a low BP goal was achieved and maintained in the large randomized trial by Hou et al. [ 40 ], but it required use of diuretics in the 80% of patients with advanced CKD.”
BackgroundProgress in retarding the progression of advanced chronic kidney disease: Grounds for optimism
BATLLE, D. C., Ramadugu, P., & Soler, M. J. (2006) · Kidney International · doi:10.1038/sj.ki.5001976 · Cited by 15
Serrano, A., Huang, J., Ghossein, C., Nishi, L., Gangavathi, A., Madhan, V., Ramadugu, P., Ahya, S. N., Paparello, J. J., Khosla, N., et al. (2007) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2006.07.009 · Cited by 15
Minutolo, R., Balletta, M., Catapano, F., Chiodini, P., Tirino, G., Zamboli, P., Fuíano, G., Russo, D., Marotta, P., Iodice, C., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5001732 · Cited by 15
Ongoing Clinical Trials in Aging-Related Tissue Fibrosis and New Findings Related to AhR Pathways
Yu, H., Feng, Z., Lin, W., Yang, K., Liu, R., Li, J., Liu, X., Pei, M., & Yang, H. (2022) · Aging and Disease · doi:10.14336/ad.2021.1105 · Cited by 17
“Until recently, angiotensin-converting-enzyme inhibitors and angiotensin-receptor blockers were the only classes of medicine that have been effective in slowing kidney function decline [128-131].”
BackgroundEpidemiology and outcomes of post-AKI proteinuria
Su, L., Li, Y., Chen, R., Zhang, X., Cao, Y., Luo, F., Pi, M., Xu, R., Gao, Q., Zhou, S., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad129 · Cited by 17
Self-citationStompór, T. P., Adamczak, M., Kurnatowska, I., Naumnik, B., Nowicki, M. P., Tylicki, L., Winiarska, A., & Krajewska, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165184 · Cited by 20
“022, respectively), with no expense of additional risk of adverse events [73].”
BackgroundInfluentialRenin Angiotensin Inhibition and Lower Risk of Kidney Failure in Patients with Heart Failure
Patel, S. S., Raman, V. K., Zhang, S., Sheriff, H. M., Fonarow, G. C., Heidenreich, P. A., Faselis, C. J., Lam, P. H., Morgan, C. J., Moore, H., et al. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.04.038 · Cited by 15
Gong, J., Zhu, W., Yu, W., Li, N., & Li, J. (2009) · PubMed · Cited by 14
Bloqueantes del receptor mineralcorticoide en la enfermedad renal crónica
Erraez, S., López-Mesa, M., & Gómez-Fernández, P. (2020) · Nefrología · doi:10.1016/j.nefro.2020.10.001 · Cited by 17
Mao, W., Zhang, L., Zou, C., Li, C., Wu, Y., Su, G., Guo, X., Wu, Y., Lu, F., Lin, Q., et al. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0830-1 · Cited by 14
“73 m(2) per year in patients with stage 4 CKD receiving benazepril [12].”
BackgroundMethodInfluentialThe current state of RAAS blockade in the treatment of hypertension and proteinuria
Kalaitzidis, R., & Bakris, G. L. (2009) · Current Cardiology Reports · doi:10.1007/s11886-009-0063-3 · Cited by 14
“Hou et al. [ 47 ] Nondiabetic proteinuric chronic nephropathy 224 Benazepril, 20 mg/d, or placebo 3.4 43% decreased in the risk of DSC, ESRD, or death; 23% decreased in the rate of decline in renal function”
BackgroundInfluentialLee, J.-H., Kwon, Y. E., Park, J. T., Lee, M. J., Oh, H. J., Han, S. H., Kang, S., Choi, K. H., & Yoo, T. (2014) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320313507122 · Cited by 14
Treatment of IgA nephropathy with renal insufficiency
Pozzi, C., Sarcina, C., & Ferrario, F. (2016) · Journal of Nephrology · doi:10.1007/s40620-015-0257-2 · Cited by 15
“group than in the placebo one [11].”
de Goeij, M. C. M., Liem, M. I., de Jager, D. J., Voormolen, N., Sijpkens, Y. W. J., Rotmans, J. I., Boeschoten, E. W., Dekker, F. W., Grootendorst, D. C., Halbesma, N., et al. (2012) · Nephron Clinical Practice · doi:10.1159/000342392 · Cited by 19
“In these patients, the median (IQR) number of available eGFR measurements was 13 (7-19) and the mean ± SD RFD was 0.”
Background2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease
Williams, M. S., Levine, G. N., Kalra, D. K., Agarwala, A., Baptiste, D., Cigarroa, J. E., Diekemper, R. L., Foster, M., Gulati, M., Henry, T. D., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.001 · Cited by 15
Framework of Guidelines for Management of CKD in Asia
Pollock, C. A., Moon, J., Ha, L. P. N., Gojaseni, P., Ching, C. H., Gomez, L., Chan, T. M., Wu, M., Yeo, S. C., Nugroho, P., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.12.010 · Cited by 15
Zhou, N., Zhao, F., Wang, L., Gao, X., Zhao, X., & Zhang, M. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c02184 · Cited by 13
Karreci, E. S., Jacas, S., Donovan, O., Pintye, D., Wiley, N., Zsengellér, Z. K., Schlöndorff, J. S., Alper, S. L., Friedman, D. J., & Pollak, M. R. (2024) · Kidney International · doi:10.1016/j.kint.2024.07.026 · Cited by 13
Teo, B. W., Ng, Z. Y., Li, J., Saw, S., Sethi, S. K., & Lee, E. J. C. (2009) · Nephrology · doi:10.1111/j.1440-1797.2009.01122.x · Cited by 13
“Also, they would benefit from aggressive retardation of kidney function deterioration so as to delay the onset of RRT.12 With increasing life expectancy in Singapore, patients with identified stage 2 CKD are at a future risk of ESRD, particularly if they are less than 40 years of age, because of the decline of GFR wit…”
BackgroundInfluentialSequential RAAS Blockade: Is It Worth the Risk?
Persson, F., & Rossing, P. R. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.01.003 · Cited by 13
Updates on medical management of hyperkalemia
Lopes, M. B., Rocha, P. N., & Pecoits‐Filho, R. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000530 · Cited by 13
“RAASi use in preventing adverse outcomes in advanced CKD is not clear, with only one trial of 224 participants with CKD G4 testing the role of an angiotensin-converting enzyme (ACEi) [29].”
BackgroundLiu, B., Wang, Q., Wang, Y., Wang, J., Zhang, L., Zhao, M., & On behalf of the C‐STRIDE study group (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13761 · Cited by 13
Ma, F., Yang, X., Zhou, M., Bai, M., Zhao, L., Li, L., Dong, R., Liu, C., Li, R., & Sun, S. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00752-x · Cited by 13
Ding, L., Yang, J., Li, L., & Yang, Y. (2020) · BioMed Research International · doi:10.1155/2020/6762029 · Cited by 13
“Previous studies demonstrated that using angiotensinconverting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could reduce the morbidity of cardiovascular events and mortality in chronic kidney disease (CKD) patients [2, 3].”
Vendeville, N., Lepage, M.-A., Festa, M. C., & Mavrakanas, T. A. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.02.027 · Cited by 14
Zhao, L., Xu, C., & Xu, J. (2014) · Cardiology · doi:10.1159/000365782 · Cited by 13
Hypertension management in patients with chronic kidney disease
Palmer, B. F. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0069-z · Cited by 13
Jiang, Y., Song, T., Qiu, Y., Liu, J., Wang, X., Huang, Z., & Lin, T. (2017) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2017.07.007 · Cited by 13
“Indeed, there is evidence that ACEI/ARB use can not only reduce the risk of end-stage renal disease (ESRD) in patients with nondiabetic and diabetic stage 3 chronic kidney disease (CKD) by 56% [5] and 28% [6], respectively, but it can also reduce the risk in those with nondiabetic stage 4 CKD by 40% [7].”
BackgroundTobe, S. W., Kawecka−Jaszcz, K., Zannad, F. M., Vetrovec, G. W., Patni, R., & Shi, H. H. (2007) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2007.06949.x · Cited by 13
Benefits of Continuing RAAS Inhibitors in Advanced CKD
Gaudreault‐Tremblay, M., & Foster, B. J. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02920320 · Cited by 13
Uraemia Progression in Chronic Kidney Disease Stages 3–5 Is Not Constant
Heaf, J. G., & Mortensen, L. S. (2011) · Nephron Clinical Practice · doi:10.1159/000323391 · Cited by 12
“found ΔGFR to be 0.8 ml/min/year/ 1.73 m 2 in 456 patients with CKD in contrast to 8.8 ml/min/year/1.73 m 2 in 422 Chinese patients [”
InfluentialRitter, C. S., Zhang, S., Finch, J. L., Liapis, H., Suárez, E., Ferder, L., Delmez, J. A., & Slatopolsky, E. (2014) · Kidney & Blood Pressure Research · doi:10.1159/000355811 · Cited by 12
“Agents that inhibit RAAS, such as angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have beneficial effects in patients with both chronic renal and cardiovascular diseases [4, 5].”
BackgroundKefale, B., Tadesse, Y., Alebachew, M., & Engidawork, E. (2018) · International Journal of Nephrology · doi:10.1155/2018/2903139 · Cited by 13
“Abbreviations ACEI: Angiotensin converting enzyme inhibitor AOR: Adjusted odds ratio ARB: Angiotensin receptor blocker CCB: Calcium channel blocker CI: Confidence interval CKD: Chronic kidney disease COR: Crude odds ratio CVD: Cardiovascular disease GFR: Glomerular filtration rate MMAS-8: 8-item Morisky medication adh…”
BackgroundInfluentialRetractedKitai, Y., Doi, Y., Osaki, K., Sugioka, S., Koshikawa, M., & Sugawara, A. (2015) · Clinical and Experimental Nephrology · doi:10.1007/s10157-015-1094-2 · Cited by 13
“In contrast, recent studies demonstrated that ACEI/ARB use was associated with an improvement in renal outcome in these patients [29, 30].”
ResultLiu, X., Deng, R., Wei, X., Wang, Y., Weng, J., Lao, Y., Lu, J., Xiong, G., & Li, S. (2021) · Bioscience Reports · doi:10.1042/bsr20211598 · Cited by 12
Thilly, N., Bayat, S., Alla, F., Kessler, M., Briançon, S., & Frimat, L. (2008) · Clinical Transplantation · doi:10.1111/j.1399-0012.2008.00807.x · Cited by 12
“They are considered now to be a gold standard in the treatment of chronic kidney disease in decreasing the percentage of patients who progress to end-stage renal disease and death (2, 3).”
BackgroundReduced incidence of end stage renal disease among the elderly in Denmark: an observational study
Heaf, J. G., & Wehberg, S. (2012) · BMC Nephrology · doi:10.1186/1471-2369-13-131 · Cited by 12
“Since then a number of large studies have shown that RAS blockade prevents the development of diabetic nephropathy [6] and reduces uraemia progression by 30-40% [7-10].”
BackgroundMonitoring and Managing Urinary Albumin Excretion: Practical Advice for Primary Care Clinicians
Bakris, G. L., & Kuritzky, L. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.07.2031 · Cited by 12
Elliott, W. J. (2007) · Yearbook of Cardiology · doi:10.1016/s0145-4145(08)70051-0 · Cited by 12
Tiwari, A., Tseng, C., Kern, E. F. O., Maney, M., Miller, D. R., & POGACH, L. M. (2007) · PubMed · Cited by 12
Chronic Kidney Disease in Brazil: Current Status and Recommended Improvements
Bauer, A. C., Elias, R. M., Abensur, H., Batista, M. C., Jansen, A. M., & RIELLA, M. C. (2024) · Kidney Diseases · doi:10.1159/000538068 · Cited by 13
When to Start Population-Wide Screening for Chronic Kidney Disease: A Cost-Effectiveness Analysis
Cusick, M. M., Tisdale, R. L., Chertow, G. M., Owens, D. K., Goldhaber‐Fiebert, J. D., & Salomon, J. A. (2024) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.3892 · Cited by 14
Bansal, N., Kathuria, D., Babu, A. M., Dhiman, S., Lakhanpal, S., Prasad, K. N., Kumar, R., Tyagi, Y., Kumar, B., Singh, M. P., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00720d · Cited by 14
Conformational studies on substituted ε-caprolactams by X-ray crystallography and NMR spectroscopy
Gruber, T., Thompson, A. L., Odell, B., Bombicz, P., & Schofield, C. J. (2014) · New Journal of Chemistry · doi:10.1039/c4nj01339e · Cited by 11
Cooper, T. E., Teng, C., Tunnicliffe, D. J., Cashmore, B. A., & Strippoli, G. F. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007751.pub3 · Cited by 15
A Rationale for Epigenetic Repurposing of Hydralazine in Chronic Heart and Kidney Failure
Zeisberg, E. M., & Zeisberg, M. (2016) · Journal of Clinical Epigenetics · Cited by 11
Hypertension Management in Transition: From CKD to ESRD
Valika, A. K., & Peixoto, A. J. (2016) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.02.002 · Cited by 12
Zhang, X., Wei, Y., & Shi, M. J. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02502e · Cited by 11
Self-citationPotential risks of calcium channel blockers in chronic kidney disease
Griffin, K. A., & BIDANI, A. K. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0071-8 · Cited by 11
Cost–effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease
Adarkwah, C. C., & Gandjour, A. (2011) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.11.8 · Cited by 11
Preventing end-stage renal disease: flexible strategies to overcome obstacles
Hirsch, S. (2006) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000242171.29329.1d · Cited by 11
The importance of a correct evaluation of progression in studies on chronic kidney disease
Kamper, A. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl561 · Cited by 11
“In recent years this method has been used in several large clinical trials examining the effect of inhibitors of the renin–angiotensin system [5,6,8–10,12,15].”
BackgroundMethodHyperkalemia in Predialysis Patients
Palmer, B. F. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06060612 · Cited by 11
Balancing Efficiency and Equity in Population-Wide CKD Screening
Cusick, M. M., Tisdale, R. L., Adams, A. S., Chertow, G. M., Owens, D. K., Salomon, J. A., & Goldhaber‐Fiebert, J. D. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.4740 · Cited by 14
Electrochemistry‐Driven Seleno‐Functionalization of Diverse Organic Scaffolds: A Recent Update
Karmakar, I., Brahmachari, G., & Lee, C. (2025) · Chemistry - An Asian Journal · doi:10.1002/asia.202500817 · Cited by 10
Bajya, K. R., & Selvakumar, S. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5c02091 · Cited by 10
The glomerular endothelial glycocalyx as a therapeutic target in proteinuric kidney disease
Gamez, M., Ramnath, R. D., Butler, M. J., Foster, R. R., & Satchell, S. C. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01028-y · Cited by 17
“143,144 .”
Ştefan, G., Stancu, S. H., Zugravu, A. D., Petre, N., Secăreanu, S., Popa, O., & Căpuşă, C. S. (2022) · Medicine · doi:10.1097/md.0000000000030422 · Cited by 11
“[7] This limit of no return has been confirmed by other investigators in observational studies and further reduced to 2 mg/dL. [8,18] However, most of the performed randomized controlled trials excluded IgAN patients with eGFR under 30 mL/min/1.73 m 2 and enrolled few patients with eGFR between 30…”
BackgroundInfluentialInampudi, C., Alvarez, P. A., Asleh, R., & Briasoulis, Α. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x14666180123164916 · Cited by 10
Wang, S., Guillot, R., Carpentier, J., Sarazin, Y., Bour, C., Gandon, V., & Lebœuf, D. (2019) · Angewandte Chemie · doi:10.1002/ange.201911761 · Cited by 10
Philippova, A. N., Vorobyeva, D. V., Gribanov, P. S., Godovikov, I. A., & Osipov, S. N. (2022) · Molecules · doi:10.3390/molecules27165195 · Cited by 10
Hsing, S.-C., Lu, K., Sun, C., Chien, W.-C., Chung, C., & Kao, S. (2015) · Medicine · doi:10.1097/md.0000000000001999 · Cited by 10
“By contrast, previous studies have included subjects who withdrew or were lost to follow-up, thus failing to follow their endpoints.(7,8,10,12,14) However, this study also exhibited a few limitations.”
ResultVoskamp, P. W. M., Dekker, F. W., van Diepen, M., & Hoogeveen, E. K. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.07.006 · Cited by 10
Shah, R., & Sparks, M. A. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000484 · Cited by 10
Omae, K., Ogawa, T., & Nitta, K. (2010) · Heart and Vessels · doi:10.1007/s00380-009-1188-4 · Cited by 10
“Additionally, ACEI is considered effective against severe renal disorder, and Hou et al.(23) have reported that the risk for terminal renal failure was lowered by 43% in patients with S-Cr of 3.”
BackgroundInfluentialHishida, E., & Nagata, D. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000541939 · Cited by 10
Hashimoto, N., Sakaguchi, Y., Hattori, K., Kawano, Y., Kawaoka, T., Doi, Y., Oka, T., Kusunoki, Y., Yamamoto, S., Yamato, M., et al. (2025) · Hypertension Research · doi:10.1038/s41440-025-02218-8 · Cited by 11
Mechanisms and therapeutic potential of multiple forms of programmed cell death in renal fibrosis
Chen, Y., Liu, F., Dai, R., Cheng, M., Wang, W., Sang, Y., Wei, L., Wang, Y., & Zhang, L. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111926 · Cited by 11
Villain, C., Metzger, M., Liabeuf, S., Hamroun, A., Laville, S. M., Mansencal, N., Combe, C., Fouque, D. P., Frimat, L., Jacquelinet, C., et al. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.10.019 · Cited by 11
Marques, F. C., Reis, J., Godinho, I., Pereira, M., Fernandes, P., Jorge, S. C., Lopes, J. A., & Gameiro, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195968 · Cited by 9
“001) and a 23% reduction in the rate of decline of the kidney function [31].”
Background
Metadata
- Authors
- Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., & Geng, R. W.
- Affiliations
- Nanfang Hospital (CN)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-01-12
- Volume
- 354
- Issue
- 2
- Pages
- 131-140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2063210769
- Cited by
- 710
- References
- 22
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 31 · 2023: 42 · 2022: 42 · 2021: 43 · 2020: 31 · 2019: 43 · 2018: 28 · 2017: 23 · 2016: 29 · 2015: 24 · 2014: 39 · 2013: 30 · 2012: 39
- FWCI
- 31.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- benazepril, ACE inhibitors, end-stage renal disease, renal protection, proteinuria, renal function decline, serum creatinine doubling, non-diabetic patients, adverse events
- MeSH terms
- Adult, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzazepines, Blood Pressure, China, Creatinine, Double-Blind Method, Female, Humans, Kidney Failure, Chronic, Male, Middle Aged, Proteinuria, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.